Histopathological characterization of ductal carcinoma in situ (DCIS) of the breast according to HER2 amplification status and molecular subtype
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Histopathological characterization of ductal carcinoma in situ (DCIS) of the breast according to HER2 amplification status and molecular subtype
Authors
Keywords
HER2 amplification, Copy number, Clusters, Ductal carcinoma in situ, Breast
Journal
VIRCHOWS ARCHIV
Volume 465, Issue 3, Pages 275-289
Publisher
Springer Nature
Online
2014-06-28
DOI
10.1007/s00428-014-1609-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Distinguishing Score 0 From Score 1+ in HER2 Immunohistochemistry-Negative Breast Cancer
- (2013) Kathleen Lambein et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
- (2013) A. Goldhirsch et al. ANNALS OF ONCOLOGY
- HER-2 overexpression is not associated with increased ipsilateral breast tumor recurrence in DCIS treated with breast-conserving surgery followed by radiotherapy
- (2013) Jae Myoung Noh et al. BREAST
- Clinicopathologic, mammographic, and sonographic features in 1,187 patients with pure ductal carcinoma in situ of the breast by estrogen receptor status
- (2013) Gaiane M. Rauch et al. BREAST CANCER RESEARCH AND TREATMENT
- Preliminary results of centralized HER2 testing in ductal carcinoma in situ (DCIS): NSABP B-43
- (2013) Kalliopi P. Siziopikou et al. BREAST CANCER RESEARCH AND TREATMENT
- Stromal architecture and periductal decorin are potential prognostic markers for ipsilateral locoregional recurrence in ductal carcinomain situof the breast
- (2013) Mieke Van Bockstal et al. HISTOPATHOLOGY
- Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
- (2013) Antonio C. Wolff et al. JOURNAL OF CLINICAL ONCOLOGY
- Treatment of Ductal Carcinoma In Situ After Excision: Would a Prophylactic Paradigm Be More Appropriate?
- (2013) R. S. Punglia et al. JNCI-Journal of the National Cancer Institute
- HER2/neu and Ki-67 expression predict non-invasive recurrence following breast-conserving therapy for ductal carcinoma in situ
- (2012) E Rakovitch et al. BRITISH JOURNAL OF CANCER
- Is DCIS Breast Cancer, and How Do I Treat it?
- (2012) N. Bijker et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- Retinoblastoma and Phosphate and Tensin Homolog Tumor Suppressors: Impact on Ductal Carcinoma In Situ Progression
- (2012) Erik S. Knudsen et al. JNCI-Journal of the National Cancer Institute
- Leptin increases HER2 protein levels through a STAT3-mediated up-regulation of Hsp90 in breast cancer cells
- (2012) Cinzia Giordano et al. Molecular Oncology
- Prognostic markers and long-term outcomes in ductal carcinoma in situ of the breast treated with excision alone
- (2011) Phoebe Holmes et al. CANCER
- Expression of HER2neu in Ductal Carcinoma in situ is Associated with Local Recurrence
- (2011) K. Han et al. CLINICAL ONCOLOGY
- Long-Term Outcomes of Invasive Ipsilateral Breast Tumor Recurrences After Lumpectomy in NSABP B-17 and B-24 Randomized Clinical Trials for DCIS
- (2011) I. L. Wapnir et al. JNCI-Journal of the National Cancer Institute
- Molecular subtyping of DCIS: heterogeneity of breast cancer reflected in pre-invasive disease
- (2010) S E Clark et al. BRITISH JOURNAL OF CANCER
- A new pathological system for grading DCIS with improved prediction of local recurrence: results from the UKCCCR/ANZ DCIS trial
- (2010) S E Pinder et al. BRITISH JOURNAL OF CANCER
- HER2and Chromosome 17 Effect on Patient Outcome in the N9831 Adjuvant Trastuzumab Trial
- (2010) Edith A. Perez et al. JOURNAL OF CLINICAL ONCOLOGY
- Relationship between pathological features, HER2 protein expression and HER2 and CEP17 copy number in breast cancer: biological and methodological considerations
- (2010) K. Lambein et al. JOURNAL OF CLINICAL PATHOLOGY
- Biomarker Expression and Risk of Subsequent Tumors After Initial Ductal Carcinoma In Situ Diagnosis
- (2010) K. Kerlikowske et al. JNCI-Journal of the National Cancer Institute
- Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial
- (2010) Jack Cuzick et al. LANCET ONCOLOGY
- HER2-positive status is an independent predictor for coexisting invasion of ductal carcinoma in situ of the breast presenting extensive DCIS component
- (2010) Ning Liao et al. PATHOLOGY RESEARCH AND PRACTICE
- Gene amplification in ductal carcinoma in situ of the breast
- (2009) L. Burkhardt et al. BREAST CANCER RESEARCH AND TREATMENT
- Prognostic Significance of Oncogenic Markers in Ductal Carcinoma In Situ of the Breast: A Clinicopathologic Study
- (2009) Sevilay Altintas et al. Breast Journal
- HER-2/neu Overexpression as a Predictor for the Transition from In situ to Invasive Breast Cancer
- (2009) R. E. Roses et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Guidelines for Human Epidermal Growth Factor Receptor 2 Testing: Biologic and Methodologic Considerations
- (2009) Guido Sauter et al. JOURNAL OF CLINICAL ONCOLOGY
- Significance of HER2 Protein Examination in Ductal Carcinoma In Situ
- (2009) Yoshiya Horimoto et al. JOURNAL OF SURGICAL RESEARCH
- Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer
- (2009) Maggie C. U. Cheang et al. JNCI-Journal of the National Cancer Institute
- COX-2 and PPARγ expression are potential markers of recurrence risk in mammary duct carcinoma in-situ
- (2008) Swati Kulkarni et al. BMC CANCER
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search